|Dr. Julian Adams||CEO & Director||580k||N/A||1955|
|Mr. Shai Lankry||Chief Financial Officer||200k||N/A||1976|
|Dr. Ronit Simantov||Chief Medical Officer||436k||N/A||1965|
|Mr. Joshua D. Hamermesh MBA||Chief Bus. Officer||283k||N/A||1972|
|Dr. Tony Peled||Co-Founder, CTO and VP of R&D||N/A||N/A||1954|
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Gamida Cell Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.